|
ES2156149T3
(es)
|
1992-12-04 |
2001-06-16 |
Medical Res Council |
Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
|
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
IT1320715B1
(it)
|
2000-10-19 |
2003-12-10 |
Cselt Centro Studi Lab Telecom |
Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e
|
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
CA2453822C
(en)
|
2001-08-03 |
2011-02-22 |
Tyco Healthcare Group Lp |
Tissue marking apparatus and method
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
JP5225069B2
(ja)
|
2005-03-23 |
2013-07-03 |
ゲンマブ エー／エス |
多発性骨髄腫の治療のためのｃｄ３８に対する抗体
|
|
TW200745162A
(en)
|
2005-05-24 |
2007-12-16 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
|
|
WO2008037257A2
(en)
|
2006-09-26 |
2008-04-03 |
Genmab A/S |
Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
|
|
CA2727278A1
(en)
|
2008-06-16 |
2010-01-21 |
Immunogen, Inc. |
Novel synergistic effects
|
|
SMT202000031T1
(it)
|
2010-06-09 |
2020-03-13 |
Genmab As |
Anticorpi contro cd38 umano
|
|
DK2621531T3
(en)
|
2010-09-27 |
2017-02-27 |
Morphosys Ag |
ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
|
UA118255C2
(uk)
*
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
|
ES2654093T3
(es)
*
|
2013-03-13 |
2018-02-12 |
Inflammatory Response Research, Inc. |
Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
WO2016022589A2
(en)
|
2014-08-08 |
2016-02-11 |
The Regents Of The University Of California |
Methods for treating multiple myeloma
|
|
PH12017500442B1
(en)
|
2014-09-09 |
2023-05-24 |
Janssen Biotech Inc |
Combination therapies with anti-cd38 antibodies
|
|
MA41555A
(fr)
|
2015-02-17 |
2017-12-26 |
Millennium Pharm Inc |
Polythérapie pour le traitement du cancer
|
|
EA201792546A1
(ru)
|
2015-05-20 |
2018-04-30 |
Янссен Байотек, Инк. |
Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
|
|
US20170121417A1
(en)
|
2015-11-03 |
2017-05-04 |
Janssen Biotech, Inc. |
Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
|
|
CA3004152C
(en)
*
|
2015-11-03 |
2024-04-16 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-cd38 antibodies and their uses
|
|
MA45674A
(fr)
*
|
2016-07-15 |
2019-05-22 |
Takeda Pharmaceuticals Co |
Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
|
|
US20180117150A1
(en)
*
|
2016-11-01 |
2018-05-03 |
Janssen Biotech, Inc. |
Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
|
|
JP7516047B2
(ja)
*
|
2016-11-23 |
2024-07-16 |
アセチロン ファーマシューティカルズ インコーポレイテッド |
ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法
|
|
MA50514A
(fr)
*
|
2017-10-31 |
2020-09-09 |
Janssen Biotech Inc |
Méthodes de traitement du myélome multiple à haut risque
|
|
WO2020194242A1
(en)
*
|
2019-03-28 |
2020-10-01 |
Janssen Biotech, Inc. |
Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with pomalidomide and dexamethasone
|
|
EP3969004A1
(en)
*
|
2019-05-14 |
2022-03-23 |
Sanofi |
Methods of administering anti-cd38 antibody to treat multiple myeloma
|